| General Information | |
|---|---|
| ZINC ID | ZINC000045300297 |
| Molecular Weight (Da) | 494 |
| SMILES | Cc1c(-c2cn(Cc3ccccc3)cn2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C26Cl3N4 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 135.037 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| LogP | 7.882 |
| Activity (Ki) in nM | 14.1254 |
| Polar Surface Area (PSA) | 35.64 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.111 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 28 |
| Fraction csp3 | 0.08 |
| Ilogp | 4.51 |
| Xlogp3 | 7.19 |
| Wlogp | 7.72 |
| Mlogp | 5.31 |
| Silicos-it log p | 6.77 |
| Consensus log p | 6.3 |
| Esol log s | -7.73 |
| Esol solubility (mg/ml) | 0.00000921 |
| Esol solubility (mol/l) | 1.87E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.76 |
| Ali solubility (mg/ml) | 0.00000857 |
| Ali solubility (mol/l) | 1.73E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.96 |
| Silicos-it solubility (mg/ml) | 5.43E-09 |
| Silicos-it solubility (mol/l) | 1.10E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.21 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.56 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.11 |
| Logd | 5.489 |
| Logp | 6.638 |
| F (20%) | 0.011 |
| F (30%) | 0.01 |
| Mdck | - |
| Ppb | 98.88% |
| Vdss | 3.206 |
| Fu | 1.84% |
| Cyp1a2-inh | 0.557 |
| Cyp1a2-sub | 0.167 |
| Cyp2c19-inh | 0.928 |
| Cyp2c19-sub | 0.06 |
| Cl | 7.704 |
| T12 | 0.03 |
| H-ht | 0.064 |
| Dili | 0.983 |
| Roa | 0.14 |
| Fdamdd | 0.719 |
| Skinsen | 0.12 |
| Ec | 0.003 |
| Ei | 0.02 |
| Respiratory | 0.023 |
| Bcf | 3.79 |
| Igc50 | 5.252 |
| Lc50 | 6.955 |
| Lc50dm | 5.806 |
| Nr-ar | 0.027 |
| Nr-ar-lbd | 0.012 |
| Nr-ahr | 0.904 |
| Nr-aromatase | 0.987 |
| Nr-er | 0.835 |
| Nr-er-lbd | 0.424 |
| Nr-ppar-gamma | 0.007 |
| Sr-are | 0.957 |
| Sr-atad5 | 0.338 |
| Sr-hse | 0.876 |
| Sr-mmp | 0.951 |
| Sr-p53 | 0.925 |
| Vol | 470.816 |
| Dense | 1.045 |
| Flex | 0.179 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.251 |
| Synth | 2.481 |
| Fsp3 | 0.077 |
| Mce-18 | 27 |
| Natural product-likeness | -1.372 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |